AI assistant
UCB — Share Issue/Capital Change 2022
Feb 4, 2022
4017_dirs_2022-02-04_6d1a145f-f151-4448-badb-cfb662009445.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Disposals of own shares
Brussels (Belgium), 4 February 2022 – 20:00 (CET) – regulated information
Disposal of own shares
In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:
| Date of transaction | Time | LTI Plan | Number of disposed UCB shares |
Price |
|---|---|---|---|---|
| 31 January 2022 | 09:51:26 | Stock Option Plan 2012 | 100 | € 32,36 |
| 31 January 2022 | 14:37:27 | Stock Option Plan 2012 | 1.900 | € 32,36 |
| 01 February 2022 | 12:50:10 | Stock Option Plan 2013 | 1.500 | € 48,69 |
| 01 February 2022 | 13:13:23 | Stock Option Plan 2012 | 500 | € 32,36 |
This press release is available on UCB SA/NV's website via the following link.
Investor Relations
Antje Witte Investor Relations, UCB
T +32 2 559 94 14, [email protected] Corporate Communications
Laurent Schots Media Relations, UCB
T+32.2.559.92.64 [email protected]
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news